You were losing weight steadily on Ozempic — 1–2 pounds per week, appetite dramatically reduced, cravings under control. Then, somewhere between month 3 and month 6, the scale stopped moving....
Read the Full Guide →Comprehensive, pharmacist-reviewed guides on the health questions our readers ask most.
You were losing weight steadily on Ozempic — 1–2 pounds per week, appetite dramatically reduced, cravings under control. Then, somewhere between month...
Starting Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication changes how your body handles food — but most patients are never told...
On April 1, 2026, the FDA approved Eli Lilly’s Foundayo (orforglipron) — the first oral GLP-1 receptor agonist for weight loss that...
Most 16:8 intermittent fasting meal plans you find online were not designed for women. They were generic, gender-neutral templates that ignore the...
The single biggest reason patients abandon semaglutide before it works is unmanaged side effects in the first few weeks. If you know...
For the first time, we have a direct, head-to-head clinical trial answering the question millions of people are asking: Zepbound vs Wegovy...
Most health content online is written by SEO writers, not clinicians. We do things differently.
Every article is written or medically reviewed by Dr. Faryal Faisal, PharmD — with clinical training at major hospitals.
We cite NEJM, JAMA, FDA, and NIH — not other health blogs. Every claim is verifiable.
We don't take payment from drug companies, supplement brands, or telehealth providers.
Every article is human-written with clinical rigor. No AI content, no thin affiliate posts.
Every category contains pharmacist-reviewed guides written for real decisions.
Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo
16:8, 20:4, protocols for special populations
Meal plans, food guides, supplement reviews
PCOS, menopause, hormonal weight changes
Panic attacks, anxiety, evidence-based support
Autoimmune, respiratory health, physical therapy
Start Being Healthy publishes health guides with the same rigor a clinician would apply — but in language a non-clinician can understand. Every article is medically reviewed by Dr. Faryal Faisal, PharmD to ensure clinical accuracy and safety before publication.
Our newest pharmacist-reviewed guides — updated regularly with the latest clinical evidence.
Simple, accurate tools designed to answer specific health questions in seconds.
Quick answers to what people ask us most. For deep answers, browse our guides.
Yes. Every article on this site is written or medically reviewed by Dr. Faryal Faisal, PharmD — a licensed pharmacist with clinical training at Dr. Ziauddin Hospital and the Karachi Institute of Kidney Diseases. Read more about our editorial process.
Based on head-to-head clinical trial data, tirzepatide (Zepbound/Mounjaro) produces the greatest average weight loss at 20.2% at 72 weeks. Semaglutide (Wegovy/Ozempic) produces around 14.9%. The newer oral option Foundayo (orforglipron) produces around 11.2%. See our full comparison guide for details.
Combining intermittent fasting with GLP-1 medications can be safe for some patients but carries specific risks — including hypoglycaemia and accelerated muscle loss. Always consult your prescriber before combining fasting with weight loss medications.
The main categories to limit are high-fat and fried foods (worst offenders for nausea), sugary foods and refined carbs, alcohol (hypoglycaemia risk), and ultra-processed foods. See our complete pharmacist's foods to avoid guide.
Weight loss plateaus affect 60-70% of GLP-1 patients between months 3-6. Common causes include metabolic adaptation, muscle loss, ghrelin rebound, and inadequate protein. Our 7-step plateau fix guide covers the breakthrough protocol.
No. We do not accept payment from pharmaceutical companies, supplement brands, weight loss programs, or telehealth providers in exchange for editorial coverage. Our recommendations reflect the clinical evidence — not commercial interests.
